Company is targeting upstream aspects of native protein degradation pathways to develop new therapies for cancer
Adapsyn Bioscience Inc., a biotechnology company focused on the discovery and development of novel medicines derived from evolved small molecule natural products, announced that it has completed a round of financing that was co-funded by Pfizer R&D Innovate and Genesys Capital. In addition, the company has announced a research collaboration with Pfizer Inc.
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.